TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: HADS anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibacterial efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: completion rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of 1:1 clinical observation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 11‐DTB2 level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Peak pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McGill Pain Questionnaire scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral changes in irritability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral changes in restlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: complete cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mycologic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: effective treatment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in syphilis knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean steady-state valproic acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of valproic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum concentration of valproic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in plasma lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of dry socket (DS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma detection rate (ADR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average number of polyps detected per colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average number of adenomas detected per colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: periodontal measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for taste of ranitidine formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of time with intragastric pH <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reocclusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EED prevalence (L:M > 0.07)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-tonsillectomy pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEI of the aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CEI of the spleen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spleen-to-liver contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median annualized attack rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median rescue medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients attack-free
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discontinuation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperkalemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: maximum plasma concentration (C max) geometric mean ratio (GMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: area under the concentration-time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of R(0)-resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of pN(0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Rate of positive lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Sensitivity of digital rectal examination for prostate cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate at first puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved functional outcome at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of detected lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: temporary catheter replacement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: median hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: CCR5 expression on CD4 T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glomerular Filtration Rate (GFR) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Contrast Medium-induced Acute Renal Failure (ARF)
Endpoint domain: Adverse events/effects
Primary endpoint: Early-stage diagnosis of PLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of alternative strategies for diabetes control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correction of spinal deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cement leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Airway hyperresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FENO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tryptase density in airway mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically detected genital lesions
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported side effects
Endpoint domain: Adverse events/effects
Primary endpoint: incident sexually transmitted diseases
Endpoint domain: Adverse events/effects
Primary endpoint: duration of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent in intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm birth rate
Endpoint domain: Mortality/survival
Primary endpoint: Coronary outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative inflammation control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in centrilobular areas of high attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dilatation of the proximal airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: NT-proBNP reduction of >30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality and HF readmissions
Endpoint domain: Mortality/survival
Primary endpoint: Median number of days alive outside of the hospital
Endpoint domain: Mortality/survival
Primary endpoint: Birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Time to first rescue analgesia (TTFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: peri-implant bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of ECG-LVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUSCAN pain domain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to complete the run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of serum HA, LN, PCIII and CIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and urinary outcomes
Primary endpoint: Liver functional tests (total bilirubin, ALT, albumin/globulin ratio, cholylglycine, serum ferritin, prealbumin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and urinary outcomes
Primary endpoint: Allergen concentration level necessary to reach reaction threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival itching (symptom score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema (percent conjunctival surface)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E-RS: COPD total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGRQ domain scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CAT score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Leukorrhagia and vaginal irritation symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: General satisfaction rate for gel use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease relapse
Endpoint domain: Mortality/survival
Primary endpoint: ISGD (Insulin-Stimulated Glucose Disposal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nonoxidative glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fasting insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in FEV1 from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall success rate in recanalising occluded vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gingival inflammation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of hygiene index (QHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychotic-like experiences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced amygdala connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in threat perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Enhanced socio-emotional regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medical knowledge about PTC and RAI treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CEC area expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CEC loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of high-grade prostate cancer (Gleason grade 7, 8, 9, or 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sexual side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of cervical aROM measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test performance parameters (sensitivity, specificity, positive predictive value, negative predictive value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interreader reproducibility (κ values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exercise tolerance (VO2max/% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal bacterial colonization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduced risk of back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: postoperative survival rate
Endpoint domain: Mortality/survival
Primary endpoint: pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA methylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Everyday multitasking performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Metacognitive task appraisals
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of lymph nodes correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged PT and aPTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decreased VIII:C and vWF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Impaired platelet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: subsequent increased mortality
Endpoint domain: Mortality/survival
Primary endpoint: overall self-harm episodes per person-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sex hormone-binding globulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lipid metabolism effects (triglycerides and lipoproteins)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMS frequency relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMS severity relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMS bother relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first passage of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative antiemetic need
Endpoint domain: Adverse events/effects
Primary endpoint: Mean creatinine concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine clearance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cases of CMN
Endpoint domain: Adverse events/effects
Primary endpoint: Cuff pressure > 22 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracuff nitrous oxide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isometric abdominal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of pelvic lymph nodes yielded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative urinary dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: axitinib plasma exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical skill performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Norepinephrine concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean log reduction factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of good responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative rates of grade 3 and 4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Serum H‐FABP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of healed ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved nidus delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strike through rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma Lp[a] concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: low-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relief of postembolization syndrome symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement of liver function damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of febrile seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Lesion improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lesion resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of acid reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of DGER
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ΔE value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: number of depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of time spent in a depressive episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal SMN1 gene copy numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Living independently
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean serum IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WBC cystine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neck and arm pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total range of motion maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rate of weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine urate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression in at least one native vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: breast tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes